Abcellera Biologics Inc ABCL

$11.13 -1.15 (-9.36%)

Valuation

Market cap
3,765,183,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,131,800
Avg volume
4,469,752
Day's range
$10.76 – $11.88
Shares out
306,611,000
Stochastic %K
12%
Beta
1.59
Analysts
Strong Buy
Price target
$17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Nov 5, 10:21 PM
$ABCL $HIMS $PFE $REGN $SYRE
0 replies
Stocktradesmoon Nov 5, 10:03 PM
$ABCL $HIMS $REGN $PFE $MRNA Wow another conference added to an already jam packed month 👀 🚨AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
1 replies
Stocktradesmoon Nov 5, 9:59 PM
$ABCL $HIMS $REGN $SYRE $PFE ABcellera just announced another conference that they will be presenting at this month: 👀 https://investors.abcellera.com/news/news-releases/2026/AbCellera-to-Present-at-the-UBS-Global-Biopharma-Conference-on-November-17-2026/default.aspx
0 replies
Ckkung71 Nov 5, 9:08 PM
$ABCL New day, low volume, playground for shorters and I bought some. On Monday it’s time for the company to show the shorters why they don’t want to borrow 20 millions new shares to destroy the price targets.
1 replies
Stocktradesmoon Nov 5, 8:47 PM
$ABCL $REGN $PFE $SLS $LLY
2 replies
XxZeeMoneyxX Nov 5, 8:43 PM
$ABCL Another great opportunity to acquire more shares at a solid discount….. Don’t get shook, stay the course…. Do your due diligence….. Time will reward the strong investors.
0 replies
Stocktradesmoon Nov 5, 8:29 PM
$ABCL $MRNA $PFE $REGN $SLS
2 replies
Stocktradesmoon Nov 5, 8:28 PM
$ABCL $REGN $PFE $MRNA $SLS @Ckkung71 Millions of shares have been bought in the last few days ( by hedge fund managers/institutions) ahead of big news 🗞️ . By next Friday we could be trading at $20.00+ 👀
1 replies